Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

NCT00073723 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00073723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00073723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
December 31, 2003
Completion date
January 31, 2007
Enrollment
75
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer